Primary central nervous system lymphoma in daily practice and the role of autologous stem cell transplantation in relapsed disease: A retrospective multicenter study

Basit Öğe Kaydı
dc.authoridBERBER, Ilhami/0000-0003-3312-8476
dc.authoridDogu, Mehmet Hilmi/0000-0001-7237-2637
dc.authoridbilen, yusuf/0000-0003-2387-4010
dc.authoridErkurt, Mehmet Ali/0000-0002-3285-417X
dc.authoriddemir, cengiz/0000-0001-9856-184X
dc.authoridKAYA, Emin/0000-0001-8605-8497
dc.authoridAltuntas, Fevzi/0000-0001-6872-3780
dc.authorwosidBERBER, Ilhami/ABI-6231-2020
dc.authorwosidDogu, Mehmet Hilmi/W-2255-2017
dc.authorwosidŞencan, Mehmet/AAA-9163-2022
dc.authorwosidbilen, yusuf/ABH-9885-2022
dc.authorwosidKorkmaz, Serdal/IST-3736-2023
dc.authorwosidErkurt, Mehmet Ali/ABI-7232-2020
dc.authorwosiddemir, cengiz/JZE-3811-2024
dc.contributor.authorErkurt, Mehmet Ali
dc.contributor.authorBerber, Ilhami
dc.contributor.authorTekgunduz, Emre
dc.contributor.authorDogu, Mehmet Hilmi
dc.contributor.authorKorkmaz, Serdal
dc.contributor.authorDemir, Cengiz
dc.contributor.authorYilmaz, Mehmet
dc.date.accessioned2024-08-04T20:41:28Z
dc.date.available2024-08-04T20:41:28Z
dc.date.issued2016
dc.departmentİnönü Üniversitesien_US
dc.description.abstractWe investigated the course of 54 patients presenting with primary central nervous system lymphoma, who were treated in daily practice. The patients were treated with chemotherapy and/or radiotherapy and/or intrathecal chemotherapy. At a median follow-up period of 23 months (range 1-71), median relapse-free survival (RFS) and overall survival (OS) were not reached. Estimated 2-year RFS and OS rates were 42% and 48%, respectively. Ten relapsed PCNSL patients underwent ASCT. Complete remission rate of these patients was 40%, with 20% treatment-related mortality. Estimated 2-year RFS and OS rates were 37% and 40%, respectively. The prognosis of patients with PCNSL, who received off-study treatment, is still dismal. (c) 2016 Elsevier Ltd. All rights reserved.en_US
dc.identifier.doi10.1016/j.transci.2016.01.018
dc.identifier.endpage84en_US
dc.identifier.issn1473-0502
dc.identifier.issue1en_US
dc.identifier.pmid26810141en_US
dc.identifier.scopus2-s2.0-84956890309en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage80en_US
dc.identifier.urihttps://doi.org/10.1016/j.transci.2016.01.018
dc.identifier.urihttps://hdl.handle.net/11616/97151
dc.identifier.volume54en_US
dc.identifier.wosWOS:000374614700015en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherPergamon-Elsevier Science Ltden_US
dc.relation.ispartofTransfusion and Apheresis Scienceen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectAutologous stem cell transplantationen_US
dc.subjectCNS lymphomaen_US
dc.subjectPCNSLen_US
dc.subjectMethotrexateen_US
dc.subjectHigh-dose chemotherapyen_US
dc.titlePrimary central nervous system lymphoma in daily practice and the role of autologous stem cell transplantation in relapsed disease: A retrospective multicenter studyen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu